ACC Media Center/X
Aug 29, 2025, 19:08
American College of Cardiology Highlights LoDoCo2 Trial on Colchicine, Blood Cancer Risk, and Heart Health
ACC (American College of Cardiology) Media Center posted on X:
”Taking low-dose colchicine daily may slow the progression of a common acquired gene mutation found in the blood of older adults that can lead to certain blood cancers and increased risk of cardiovascular disease, according to a subanalysis of the LoDoCo2 trial published in JACC and presented at ESC Congress.”
Read the full study here.
Stay updated with Hemostasis Today.
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal
-
Jul 23, 2026, 13:46Sebastian Szmit: Understanding Troponins in Modern Cardio-Oncology
-
Jul 23, 2026, 13:41Colleen Grady: Why Normal Hemoglobin Does Not Exclude Iron Deficiency
-
Jul 23, 2026, 13:22Jacob Kelly: AHA Review Highlights Coffee’s Cardiovascular Benefits